

Anti-DLL3 Antibody (Rovalpituzumab)

Introduction

Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-active molecule conjugates (ADCs), Rovalpituzumab Tesirine. Rovalpituzumab has anti-small cell lung cancer (SCLC) activity.

Product parameters

Alternative Names	Rovalpituzumab
Target Accession	Q9NYJ7
Target	DLL3
CAS number	1613313-01-1
Molecular Weight	145.02 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human DLL3 His at 2 ug/mL can bind Anti-DLL3 Antibody (Rovalpituzumab), EC50=0.01407 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

